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G. William Dec, MDC ardiac resynchronization-deﬁbrillation ther-apy (CRT-D) is now a well-established treat-ment for patients with symptomatic heart
failure unresponsive to optimized pharmacological
therapy, including an angiotensin-converting
enzyme inhibitor or angiotensin receptor blocker
and a beta-adrenergic blocker (1). Current indications
based on American College of Cardiology (ACC)/
American Heart Association (AHA) practice guidelines
include patients with New York Heart Association
(NYHA) functional class II to IV symptoms, left
bundle branch block (LBBB), and QRS duration of
150 ms or more (2). Patients with LBBB and QRS
duration of 120 to 149 ms or non-LBBB and QRS dura-
tion of 150 ms or more also have been reported to
beneﬁt from CRT-D therapy on the basis of earlier
clinical trial results. Recently, the long-term results
of the MADIT-CRT (Multicenter Automatic Deﬁbril-
lator Implantation Trial with Cardiac Resynchroniza-
tion Therapy) trial demonstrated improved survival
among patients with mild (NYHA functional class I
or II) symptoms (3). Despite more than a decade of
progress in improving implantation techniques and
optimizing pacing, approximately 30% of patients
still fail to respond adequately to CRT-D therapy.
Given its invasive nature and the signiﬁcant health-
care costs, accurate identiﬁcation of those patients
most likely to beneﬁt remains a clinical challenge.
Although multiple clinical trials have evaluated a
myriad of echocardiographic parameters to assess
ventricular dyssynchrony, these measures have
generally failed to differentiate responders from*Editorials published in the Journal of the American College of Cardiology
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CRT (Echocardiography Guided Cardiac Resynchro-
nization) trial conﬁrmed the powerful predictive
value of QRS duration, but not dyssynchrony mea-
sures, in identifying responsive patients (5). Despite
clear-cut echocardiographic conﬁrmation of ventric-
ular dyssynchrony, patients with normal QRS dura-
tion (mean 105 ms) failed to beneﬁt from CRT-D
therapy.
Attention has shifted away from dyssynchrony
assessment and once again refocused on QRS
morphology and duration as predictors of favorable
outcome (e.g., improved survival, increased exercise
duration, and left ventricular reverse remodeling).
Several recent clinical trials and meta-analyses have
shown that the presence of LBBB is predictive of a
favorable response to CRT-D (6–8). More importantly,
it is now increasingly apparent that patients with
signiﬁcant QRS prolongation but a non-LBBB
morphology may experience no beneﬁt or even sus-
tain harm from this treatment (9–11). When complete
LBBB exists, left ventricular lateral wall activation
occurs approximately 100 ms later than the inter-
ventricular septum activation due to impairment in
rapid impulse conduction via the His-Purkinje sys-
tem. The left ventricular pacing lead in CRT reduces
this delay and restores more-synchronized activation
between both ventricular walls. However, left ven-
tricular activation remains relatively intact through
the normal His-Purkinje pathway in patients with
QRS prolongation and non-LBBB morphology.SEE PAGE 887In this issue of the Journal, Zusterzeel et al. (12)
report sex-speciﬁc mortality risk by QRS mor-
phology and duration among a cohort of 31,892
patients who underwent CRT-D therapy and were
included in the NCDR (National Cardiovascular Data
Registry) Implantable Cardioverter Deﬁbrillator (ICD)
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896registry. The study population included patients
with either ischemic (56%) or nonischemic cardio-
myopathy (44%) and predominantly NYHA func-
tional class III symptoms (83%) who underwent
device implantation between 2006 and 2009. Unlike
previously published clinical trials or registries in
which women have comprised 22% to 30% of the
study population, females represented 36% of this
large cohort. Although mean left ventricular ejection
fraction (LVEF) did not differ between men and
women (mean LVEF 24  7%), signiﬁcantly more
women had LBBB at baseline (86% vs. 70%) and a
nonischemic heart failure etiology (62% vs. 33%).
Among the entire cohort with complete LBBB,
women had a 21% lower mortality compared with
men (hazard ratio: 0.79; 95% CI: 0.74 to 0.84;
p < 0.001). Further, longer QRS duration with LBBB
was associated with better survival in both men and
women. Speciﬁcally, a QRS duration >140 ms in
women and >150 ms in men was associated with the
greatest survival beneﬁt. Importantly, no beneﬁt was
observed in either sex when QRS prolongationwas due
to non-LBBB morphology.
In the study by Loring et al. (8) of 144,642 Medi-
care beneﬁciaries who underwent CRT-D therapy
between 2002 and 2007, women composed 26% of
this cohort. Unlike the present study, women who
underwent CRT-D therapy had a higher rate of atrial
ﬁbrillation or ﬂutter (48% vs. 0%), a higher incidence
of ischemic cardiomyopathy (53% vs. 38%), and a
lower prevalence of LBBB (53% vs. 86%). Despite
substantial differences between the 2 study pop-
ulations, this large registry also reported that
women with complete LBBB demonstrated a sub-
stantially lower risk-adjusted mortality rate than
men; furthermore, heart failure hospitalizations were
decreased by 26% in women compared with 15% in
men with LBBB (8).
Why would women be more responsive to CRT-D
than men? Women normally have smaller left
ventricular cavity dimensions and shorter baseline
QRS duration. Further, women are more likely to
have “true” LBBB, whereas men are more likely to
have an incomplete LBBB at the lower end of the
QRS prolongation spectrum (e.g., 120 to 140 ms). In
addition to electrophysiological differences be-
tween sexes, ischemic cardiomyopathy remains asigniﬁcantly less common cause of symptomatic
heart failure in women.
Like all retrospective database analyses, the pre-
sent study has several limitations. It evaluated only
patients admitted for CRT-D implantation who did
not have a prior pacemaker or ICD. This trial excluded
patients with a prior history of atrial ﬁbrillation,
a group known to have a lower response rate to
CRT-D therapy. Further, no information is provided
regarding the use of aldosterone antagonists in this
population. The majority of patients (83%) had NYHA
functional class III symptoms, and the results should
be largely conﬁned to patients with this severity of
heart failure. Given the large size of the database, the
endpoint for analysis was all-cause mortality, and the
exact cause of death or percent cardiovascular deaths
was unknown. Finally, as with any observational
study, there is a possibility of unmeasured, con-
founding variables, including noncardiac comorbid-
ities. Nonetheless, this study demonstrates among
real-world CRT-D recipients a striking mortality
reduction among women with LBBB compared with
men and, as importantly, no difference between men
and women patients who exhibited substantial QRS
prolongation but lack LBBB morphology. Although
the extent of QRS prolongation was associated with
better survival in LBBB patients, this favorable prog-
nosis seems to plateau higher than 140 ms in women
and 150 ms in men. This report adds to knowledge
derived from smaller clinical trials by further identi-
fying patients more (and less) likely to respond to
CRT-D treatment. It is important to recognize that
women are frequently underrepresented in clinical
trials and less frequently receive invasive cardiac in-
terventions. Limiting CRT-D therapy to individuals
with LBBB and QRS duration of 150 ms or more may
deprive a substantial number of women with shorter
QRS duration of this beneﬁcial treatment. Conversely,
the appropriate role of CRT-D therapy in both men
and women with moderately severe heart failure
symptoms who lack LBBB morphology appears to
require careful reevaluation.
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